A5068165471- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Palliative Care and End-of-Life Issues
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer survivorship and care
- Pancreatic and Hepatic Oncology Research
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Treatments and Mutations
- Medical Imaging Techniques and Applications
- Cancer-related Molecular Pathways
- Chemotherapy-induced cardiotoxicity and mitigation
- Advanced Nanomaterials in Catalysis
- Management of metastatic bone disease
- Lung Cancer Research Studies
- Frailty in Older Adults
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Occupational and environmental lung diseases
Queen Elizabeth Hospital
2020-2025
Regeneron (United States)
2025
China Medical University
2025
Shanxi Medical University
2024
Soochow University
2024
This cohort study investigates the association between low levels of ERBB2 expression and progression-free survival among patients with HR+/ERBB2− metastatic breast cancer treated CDK4/6 inhibitors.
Glucagon stimulates hepatic glucose production, in part by promoting the uptake and catabolism of amino acids. Inhibition liver glucagon receptor (GCGR) results elevated plasma acids, which triggers proliferation pancreatic alpha-cells, forming a liver-alpha cell loop. This study aims to delineate signaling molecules downstream GCGR mediate We knocked down GCGR, its G-coupled protein GNAS, two GNAS effectors, PKA EPAC2 (RAPGEF4). Mice with knockdown had similar suppression acid genes,...
<p dir="ltr">Glucagon stimulates hepatic glucose production, in part by promoting the uptake and catabolism of amino acids. Inhibition liver glucagon receptor (GCGR) results elevated plasma acids, which triggers proliferation pancreatic alpha-cells, forming a liver-alpha cell loop. This study aims to delineate signaling molecules downstream GCGR mediate We knocked down GCGR, its G-coupled protein GNAS, two GNAS effectors, PKA EPAC2 (RAPGEF4). Mice with knockdown had similar suppression...
<p dir="ltr">Glucagon stimulates hepatic glucose production, in part by promoting the uptake and catabolism of amino acids. Inhibition liver glucagon receptor (GCGR) results elevated plasma acids, which triggers proliferation pancreatic alpha-cells, forming a liver-alpha cell loop. This study aims to delineate signaling molecules downstream GCGR mediate We knocked down GCGR, its G-coupled protein GNAS, two GNAS effectors, PKA EPAC2 (RAPGEF4). Mice with knockdown had similar suppression...
Abstract Radiotherapy plays a crucial role in the treatment of advanced breast cancer, but increased antioxidant system, especially rise glutathione (GSH), presents significant obstacle to its effectiveness. To address this challenge, versatile GSH‐depleted photodynamic nanoadjuvant is developed augment efficacy radiotherapy for cancer treatment. This operates within tumor microenvironment effectively deplete intracellular GSH through sequence cascaded processes, including exhaustion,...
Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab atezolizumab, are major classes of immune checkpoint inhibitors that increasingly used for cancer treatment. However, their use is associated with adverse cardiovascular events. We examined the incidence new-onset cardiac complications in patients receiving PD-1 or PD-L1 inhibitors.Patients since launch up to 31st December 2019 at publicly funded hospitals Hong Kong, China, without...
Cranial neuropathy is a common presenting symptom of advanced T4 nasopharyngeal carcinoma (NPC). Data on neurological outcomes after modern intensity-modulated radiotherapy (IMRT) and chemotherapy are scarce.Case records consecutive NPC patients who received definitive IMRT in two tertiary oncology centers 2004-2019 were reviewed. Patterns cranial neuropathies at disease presentation recorded. Time to recovery the rate subsequent re-palsy estimated by Kaplan-Meier method. Clinical predictors...
e13069 Background: In patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+ HER2- MBC), the correlation between level of expression HR and clinical efficacy CDK4/6 inhibitors remains undefined. Methods: We identified consecutive HR+ MBC starting a inhibitor (palbociclib, ribociclib or abemaciclib) plus either an aromatase fulvestrant Jan 2018 - Oct 2023 from institutional registry. Expression was stratified as high (H) (Allred score 7-8), moderate (M) 5-6) low...
Objectives: To explore the underlying variables and molecular pathways leading to pancreatic cancer liver metastasis. Methods: Hs766T Hs766T-L3 cells were used create in vitro vivo metastasis models. DYRK2 involvement was investigated using cell adhesion assays, wound healing migration invasion assays. examine link between expression epithelial-mesenchymal transition, Western blot, quantitative real-time PCR, immunofluorescence immunoprecipitation (IP) utilized. We found that mice with...
ABSTRACT Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab atezolizumab, are major classes of immune checkpoint inhibitors that increasingly used for cancer treatment. However, their use is associated with adverse cardiovascular events. We examined the incidence new-onset cardiac complications in patients receiving PD-1 or PD-L1 inhibitors. Methods Patients since launch up to 31 st December 2019 at publicly funded...
e24091 Background: Prognostication by predicting the likelihood of surviving at certain time points is an important aspect for clinician-patient communication, inform medical decisions and facilitate advance care planning. Understanding disease trajectory has also been reported to improve patient satisfaction in encounters reduce anxiety depression carer due unprepared clinical deterioration. The main problem applying currently available tools that included prognostic factors were designed...
1052 Background: Markers for the efficacy of CDK4/6 inhibitor in estrogen receptor (ER) positive, HER2 negative advanced breast cancer are limited. The bidirectional crosstalks that exist between ER and pathways contribute to endocrine resistance. We investigated association low levels expression clinical outcome patients with ER+ HER2- metastatic (MBC) treated inhibitors. Methods: identified consecutive MBC who received plus either letrozole or fulvestrant Mar 2017 - Jun 2020 from an...
e12592 Background: Achieving pCR following neoadjuvant chemo and anti-HER2 therapy is associated with a significantly better survival in HER2+ BC. There currently lack of robust biomarker to predict Using EFTUD2 as chromosome 17 reference probe, circulating HER2/EFTUD2 plasma DNA copy number ratio (H-ratio) detected by droplet digital PCR (ddPCR) was shown have high concordance the tumor HER2 status. We aim evaluate whether change H-ratio response dual therapy. Methods: prospectively...
1043 Background: Dual anti-HER2 antibodies pertuzumab (P) and trastuzumab (T) in combination with taxane (D), followed by PT maintenance, is the standard first line treatment for HER2 positive advanced breast cancer (HER2+ ABC). Treatment associated cardiotoxicity necessitates regular cardiac function surveillance, which a burden particularly long-responders. Data safety of prolonged P+T exposure scarce. We investigate real-world impact on long-responders to dual antibodies. Methods:...
e13584 Background: Development of non-invasive means for early detection is key to reduce gastric cancer mortality. Artificial intelligence (AI) has potential accurately identify malignancy related physiological processes including subclinical bleeding, systemic inflammation and coagulation disorder, through machine learning pattern change in routine blood profile panel, which constitute a signature cancer. The laboratory values various components the panels between diseased non-diseased...
•101 patients with HER2+ MBC on pertuzumab and trastuzumab were included.•Most observed cardiotoxicity mild, all occurred early within 24 months.•Presence of cardiovascular co-morbidities predicts treatment cardiotoxicity.•Risk-stratified de-escalation long-term cardiac surveillance should be discussed. The current standard first-line for human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) is the CLEOPATRA regimen, consisting dual anti-HER2 antibodies in...